ES2478258T3 - Formulación farmacéutica que comprende compuestos de lantano - Google Patents

Formulación farmacéutica que comprende compuestos de lantano Download PDF

Info

Publication number
ES2478258T3
ES2478258T3 ES10151270.5T ES10151270T ES2478258T3 ES 2478258 T3 ES2478258 T3 ES 2478258T3 ES 10151270 T ES10151270 T ES 10151270T ES 2478258 T3 ES2478258 T3 ES 2478258T3
Authority
ES
Spain
Prior art keywords
pharmaceutical formulation
lanthanum carbonate
lanthanum compounds
lanthanum
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10151270.5T
Other languages
English (en)
Inventor
Josephine Christine Ferdinando
Robert Paul Haslam
Laura Anna Trespidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Holdings AG
Shire Biopharmaceuticals Holdings Ireland Ltd
Original Assignee
Shire Holdings AG
Shire Biopharmaceuticals Holdings Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34221462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2478258(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Holdings AG, Shire Biopharmaceuticals Holdings Ireland Ltd filed Critical Shire Holdings AG
Application granted granted Critical
Publication of ES2478258T3 publication Critical patent/ES2478258T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una tableta masticable de carbonato de lantano, que comprende los siguientes ingredientes: Ingrediente % en peso Carbonato de lantano 26.5 Dextratos 69.3 Sílice anhidra coloidal 2.0 Talco Purificado 1.7 Estearato de magnesio 0.5 en donde el carbonato de lantano se hidrata con un contenido de agua con un valor promedio de 4 moles de agua.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10151270.5T 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano Expired - Lifetime ES2478258T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49756003P 2003-08-26 2003-08-26
US497560P 2003-08-26
US51707803P 2003-11-05 2003-11-05
US517078P 2003-11-05

Publications (1)

Publication Number Publication Date
ES2478258T3 true ES2478258T3 (es) 2014-07-21

Family

ID=34221462

Family Applications (4)

Application Number Title Priority Date Filing Date
ES09172030.0T Expired - Lifetime ES2532389T3 (es) 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano
ES04761727T Expired - Lifetime ES2343354T3 (es) 2003-08-26 2004-08-26 Formulacion farmaceutica que comprende compuestos de lantano.
ES10151270.5T Expired - Lifetime ES2478258T3 (es) 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano
ES14167982.9T Expired - Lifetime ES2592803T3 (es) 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES09172030.0T Expired - Lifetime ES2532389T3 (es) 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano
ES04761727T Expired - Lifetime ES2343354T3 (es) 2003-08-26 2004-08-26 Formulacion farmaceutica que comprende compuestos de lantano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14167982.9T Expired - Lifetime ES2592803T3 (es) 2003-08-26 2004-08-26 Formulación farmacéutica que comprende compuestos de lantano

Country Status (28)

Country Link
US (2) US7465465B2 (es)
EP (4) EP2133084B1 (es)
JP (2) JP4896719B2 (es)
KR (1) KR100830764B1 (es)
CN (1) CN1871018B (es)
AT (2) ATE460169T1 (es)
AU (2) AU2004266050B2 (es)
BR (1) BRPI0413394A8 (es)
CA (1) CA2536959C (es)
CY (2) CY1110241T1 (es)
CZ (1) CZ17621U1 (es)
DE (2) DE202004021169U1 (es)
DK (5) DK2792363T3 (es)
EA (2) EA012798B1 (es)
ES (4) ES2532389T3 (es)
FI (1) FI7568U1 (es)
HU (2) HUE024906T2 (es)
IL (2) IL173755A0 (es)
IS (1) IS2893B (es)
MX (1) MXPA06002257A (es)
NO (1) NO342559B1 (es)
NZ (1) NZ545633A (es)
PL (4) PL2792363T3 (es)
PT (4) PT2792363T (es)
SG (1) SG145765A1 (es)
SI (4) SI2133084T1 (es)
WO (1) WO2005018651A1 (es)
ZA (1) ZA200602213B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
GB0015745D0 (en) * 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US7192609B2 (en) * 2001-04-23 2007-03-20 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
JP4869229B2 (ja) * 2004-07-27 2012-02-08 シア ファーマシューティカルズ，インク． 水酸化炭酸ランタンを用いた高リン血症を治療するための医薬組成物
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
AU2005295609A1 (en) * 2004-10-15 2006-04-27 Spectrum Pharmaceuticals, Inc. Phosphate binder with reduced pill burden
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
JP2009504779A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における慢性腎不全及びその他の病気の治療：組成物及び方法
JP2009504781A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における高リン血症：治療のための組成物、及び治療方法
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
JP5623275B2 (ja) * 2007-07-31 2014-11-12 カーギル インコーポレイテッド 直接打錠可能なデキストロース
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
WO2009118760A2 (en) * 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition
WO2010085520A1 (en) * 2009-01-21 2010-07-29 Mylan Inc. Disintegrable formulations of lanthanum carbonate
WO2010106557A2 (en) * 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
AU2010313075A1 (en) * 2009-10-26 2012-05-31 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
KR101940207B1 (ko) * 2010-05-12 2019-01-18 스펙트럼 파마슈티컬즈 인크 란탄 카보네이트 하이드록사이드, 란탄 옥시카보네이트 및 이들의 제조 및 사용 방법
EP2441436A1 (de) 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
CN103127041A (zh) * 2012-02-23 2013-06-05 南京卡文迪许生物工程技术有限公司 含有醋酸镧的药物组合物及其制备方法和用途
DE102012209411A1 (de) * 2012-06-04 2013-12-05 Fim Biotech Gmbh Mineralische Verbindung zur Reduzierung von anorganischen Phosphaten, insbesondere im Rahmen einer Nierenersatztherapie
CN104473963B (zh) * 2014-12-24 2017-10-10 厦门科明达科技有限公司 稀土化学药碳酸镧咀嚼片的制备方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6093829B1 (ja) * 2015-10-02 2017-03-08 バイエル薬品株式会社 ランタン化合物を含む医薬組成物
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
EP4061340A4 (en) 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
US4877735A (en) 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
EP0620728B1 (en) * 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
PL185332B1 (pl) 1994-05-20 2003-04-30 Janssen Pharmaceutica Nv Kompozycja przeciwrobacza dla zwierząt towarzyszących człowiekowi zawierająca flubendazol
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US6270790B1 (en) * 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6160016A (en) * 1999-12-22 2000-12-12 Wisconsin Alumni Research Foundation Phosphorus binder
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) * 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
US7090875B2 (en) * 2000-12-19 2006-08-15 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
US20020122823A1 (en) 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
US7192609B2 (en) * 2001-04-23 2007-03-20 Shire International Licensing B.V. Use of rare earth compounds for the prevention of kidney stone disease
GB0201607D0 (en) 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
CA2483827C (en) * 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
MXPA06002257A (es) 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
CA2557999C (en) 2004-03-30 2013-11-12 Ilypsa, Inc. Methods and compositions for treatment of ion imbalances
US7854924B2 (en) * 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8282960B2 (en) * 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
JP4869229B2 (ja) * 2004-07-27 2012-02-08 シア ファーマシューティカルズ，インク． 水酸化炭酸ランタンを用いた高リン血症を治療するための医薬組成物
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
WO2009118760A2 (en) 2008-03-26 2009-10-01 Matrix Laboratories Limited Lanthanum composition

Also Published As

Publication number Publication date
DE202004021169U1 (de) 2007-03-01
US20050079135A1 (en) 2005-04-14
PT2172205E (pt) 2014-07-17
EP1660104A1 (en) 2006-05-31
PT1660104E (pt) 2010-06-15
SI2133084T1 (sl) 2015-07-31
AU2009202429A1 (en) 2009-07-09
EA200970709A1 (ru) 2010-04-30
EP2792363A1 (en) 2014-10-22
FIU20060387U0 (fi) 2006-09-22
JP2007503400A (ja) 2007-02-22
PL2792363T3 (pl) 2017-01-31
NO342559B1 (no) 2018-06-18
ES2592803T3 (es) 2016-12-01
ES2343354T3 (es) 2010-07-29
HUE029382T2 (en) 2017-02-28
ATE460169T1 (de) 2010-03-15
MXPA06002257A (es) 2006-05-17
BRPI0413394A (pt) 2006-10-17
HUE024906T2 (en) 2016-02-29
AT9809U1 (de) 2008-04-15
AU2004266050A1 (en) 2005-03-03
EP2792363B1 (en) 2016-06-29
DK1660104T3 (da) 2010-06-21
PT2792363T (pt) 2016-09-26
PL2133084T3 (pl) 2015-08-31
DK200600252U1 (da) 2007-01-12
JP4896719B2 (ja) 2012-03-14
CA2536959A1 (en) 2005-03-03
PT2133084E (pt) 2015-04-16
EP2133084A2 (en) 2009-12-16
BRPI0413394A8 (pt) 2016-03-08
AU2009202429B2 (en) 2012-03-22
HK1084338A1 (en) 2006-07-28
NO20061347L (no) 2006-05-15
EP2172205A1 (en) 2010-04-07
WO2005018651A1 (en) 2005-03-03
IL235371B (en) 2018-08-30
DK2133084T3 (en) 2015-04-13
US20090017133A1 (en) 2009-01-15
EP2172205B1 (en) 2014-06-18
EA200600479A1 (ru) 2006-08-25
FI7568U1 (fi) 2007-07-17
IS2893B (is) 2014-09-15
SI1660104T1 (sl) 2010-08-31
PL2172205T3 (pl) 2015-01-30
JP2010248247A (ja) 2010-11-04
DE602004025950D1 (de) 2010-04-22
SG145765A1 (en) 2008-09-29
CY1118211T1 (el) 2017-06-28
EA012798B1 (ru) 2009-12-30
IS8353A (is) 2006-03-15
CN1871018A (zh) 2006-11-29
ES2532389T3 (es) 2015-03-26
CZ17621U1 (cs) 2007-06-25
DK200600252U4 (da) 2007-11-23
ZA200602213B (en) 2009-04-29
CN1871018B (zh) 2011-11-02
CY1110241T1 (el) 2015-01-14
PL1660104T3 (pl) 2010-08-31
SI2792363T1 (sl) 2016-11-30
US7465465B2 (en) 2008-12-16
CA2536959C (en) 2011-08-02
DK2792363T3 (da) 2016-09-26
KR100830764B1 (ko) 2008-05-20
NZ545633A (en) 2009-07-31
EP2133084A3 (en) 2010-02-03
EP1660104B1 (en) 2010-03-10
KR20060118420A (ko) 2006-11-23
EP1660104A4 (en) 2006-10-18
IL173755A0 (en) 2006-07-05
DK2172205T3 (da) 2014-07-14
EP2133084B1 (en) 2015-02-18
AU2004266050B2 (en) 2009-06-18
SI2172205T1 (sl) 2014-10-30

Similar Documents

Publication Publication Date Title
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
CR6895A (es) Nuevos compuestos heterociclicos su preparacion y su utilizacion como medicamentos en especial como antibacterianos
ES2655435T3 (es) Formulación de disolución rápida de cinacalcet
UY28014A1 (es) Compuestos quimicos
ECSP055747A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
ECSP024323A (es) Compuestos organicos
NO20034627L (no) Oralt avleverbart farmasöytisk preparat innbefattende en aktiv forbindelsemed en aminosulfonylgruppe (cox-2 inhibitor) en polyetylenglykolog et friradikal-fjernende antioksidasjonsmiddel
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
HRP20120323T1 (en) Diarylhydantoin compounds
AR039701A1 (es) Combinaciones de compuestos activos fungicidas
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
NO20062098L (no) Faststofftilstandmontelukast
PE20040417A1 (es) Forma de administracion de ibuprofeno sodico
PE20070821A1 (es) Composiciones estabilizadas de carbono de lantano
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
WO2002076918A8 (fr) Inhibiteur nf-kb contenant comme principe actif un derive d'acide benzoique substitue
BR0317555A (pt) Composições farmacêuticas de sertaconazol para uso vaginal
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
AR037326A1 (es) Composicion farmaceutica de liberacion prolongada que contiene metformina
CO5700710A2 (es) Formulacion farmaceutica
PA8579901A1 (es) Bifenilcarboxamidas sustituidas con n-aril piperidina
HRP20080027T3 (hr) 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
UY27610A1 (es) Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos